Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) for the reporting period ending March 27, 2007. The filing reports the completion of a private placement of equity securities.
Key Financial Metrics
- Gross Proceeds: $1,000,000 from the sale of 400,000 units.
- Unit Price: $2.50 per unit.
- Transaction Costs: $80,300 in fees and expenses paid to the placement agent.
- Securities Issued: 400,000 shares of common stock and warrants to purchase 200,000 additional shares.
- Warrant Terms: Exercise price of $3.00 per share.
- Placement Agent Compensation: A warrant to purchase 48,000 common shares at $3.00.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, total debt, or overall liquidity.
Material Changes
The primary material change is the increase in cash assets due to the private placement and the corresponding increase in outstanding equity and warrant obligations. This transaction was an extension of an offering previously disclosed on March 15, 2007.
Outlook, Risks, and Contingencies
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of unregistered sales. Investors received registration rights regarding the underlying securities.
Key Facts for Investor Verification
- Verify the net cash impact after deducting the $80,300 in transaction fees.
- Confirm the dilution impact of the 400,000 new shares and the 200,000 warrant shares (plus 48,000 agent warrants).
- Review the Securities Purchase Agreement (Exhibit 4.1) for any restrictive covenants or use-of-proceeds limitations.
- Check subsequent filings to confirm the exercise status of the warrants issued at the $3.00 strike price.